Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Mineralys Therapeutics Inc (NASDAQ: MLYS) closed at $14.22 in the last session, down -0.21% from day before closing price of $14.25. In other words, the price has decreased by -$0.21 from its previous closing price. On the day, 0.64 million shares were traded. MLYS stock price reached its highest trading level at $14.4617 during the session, while it also had its lowest trading level at $13.8001.
Ratios:
We take a closer look at MLYS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 14.02 and its Current Ratio is at 14.02. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 10, 2024, initiated with a Buy rating and assigned the stock a target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.
On March 07, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $27.Wells Fargo initiated its Overweight rating on March 07, 2023, with a $27 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 13 ’25 when Samsara BioCapital GP, LLC bought 600,000 shares for $13.50 per share. The transaction valued at 8,100,000 led to the insider holds 5,674,916 shares of the business.
AKKARAJU SRINIVAS bought 600,000 shares of MLYS for $8,100,000 on Mar 13 ’25. The Director now owns 5,674,916 shares after completing the transaction at $13.50 per share. On Mar 13 ’25, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the Director of the company, bought 1,296,296 shares for $13.50 each. As a result, the insider paid 17,499,996 and bolstered with 4,280,051 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 892996096 and an Enterprise Value of 510475744.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.08, which has changed by 0.054896116 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $18.29, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 34.23%, while the 200-Day Moving Average is calculated to be 17.71%.
Shares Statistics:
According to the various share statistics, MLYS traded on average about 707.32K shares per day over the past 3-months and 2834140 shares per day over the past 10 days. A total of 49.82M shares are outstanding, with a floating share count of 31.01M. Insiders hold about 50.62% of the company’s shares, while institutions hold 43.38% stake in the company. Shares short for MLYS as of 1740700800 were 2013841 with a Short Ratio of 2.85, compared to 1738281600 on 1862767. Therefore, it implies a Short% of Shares Outstanding of 2013841 and a Short% of Float of 5.91.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
As of right now, 5.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.99, with high estimates of -$0.69 and low estimates of -$1.24.
Analysts are recommending an EPS of between -$2.76 and -$4.42 for the fiscal current year, implying an average EPS of -$3.89. EPS for the following year is -$3.96, with 6.0 analysts recommending between -$3.16 and -$4.88.
